Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kerry Nie

Physician Assistant, Surgical Dayton, OH Physician Assistant

NPI 1780770057 CMS profile 11079942

30 E Apple St, Ste 1480, Dayton, OH 45409

Open in the dashboard

General payments

$6,797

256 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kerry Nie of Dayton, OH is reported in the CMS Open Payments database as having received $6,797 across 256 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $833 26
2024 General $1,857 64
2023 General $1,782 66
2022 General $1,747 70
2021 General $577 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kerry Nie
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Kerry Nie were reported at $833. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Kerry Nie Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $577 $111 $36–$285 $132
2022 $1,747 $126 $44–$350 $149
2023 $1,782 $137 $47–$355 $160
2024 $1,857 $146 $49–$384 $164
2025 $833 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,157 38 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $856 42 payments
  3. Esperion Therapeutics, Inc. $830 33 payments
  4. AstraZeneca Pharmaceuticals LP $823 23 payments
  5. GlaxoSmithKline, LLC. $555 21 payments
  6. Gilead Sciences, Inc. $419 19 payments
  7. Amgen Inc. $394 15 payments
  8. IBSA Pharma Inc. $274 4 payments
  9. Ironwood Pharmaceuticals, Inc $253 13 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $207 5 payments
  11. Other $1,029 43 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,797 256 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $856 42 payments
  2. NEXLETOL $830 33 payments
  3. BREZTRI $592 10 payments
  4. TRULANCE $574 36 payments
  5. CREON $548 28 payments
  6. LINZESS $391 19 payments
  7. EVENITY $336 12 payments
  8. TRELEGY ELLIPTA $335 16 payments
  9. QULIPTA $335 3 payments
  10. NEXLIZET $300 2 payments
  11. Other $2,924 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 154 drugs

Part D claims

15,170

Median for Physician Assistant: 241

Drug cost

$1,771,826

Median for Physician Assistant: $4,110

Branded share of claims

25.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vascepa Icosapent Ethyl Brand 979 $361,538
Diclofenac Epolamine Generic 388 $168,811
Clemastine Fumarate Generic 41 $112,843
Linzess Linaclotide Brand 179 $96,746
Nexletol Bempedoic Acid Brand 222 $90,716
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 113 $71,616
Diclofenac Sodium Generic 176 $62,491
Januvia Sitagliptin Phosphate Brand 94 $54,118
Omeprazole-Sodium Bicarbonate Omeprazole/Sodium Bicarbonate Brand 52 $48,233
Xifaxan Rifaximin Brand 21 $46,114

The 10 drugs with the highest cost, of 154 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $214
$214 21 —
NEXLETOL
  • Esperion Therapeutics, Inc. $169
$169 222 —
LINZESS
  • Ironwood Pharmaceuticals, Inc $87
  • AbbVie, Inc. $80
$167 179 —
AREXVY
  • GlaxoSmithKline, LLC. $159
$159 — —
QULIPTA
  • AbbVie, Inc. $150
$150 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

256 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record